Remedy publishes financial information twice a year in the form of a half-year report and a financial statements release.

Financial targets

In the long term, the company’s aim is to create profitable growth by expanding the product portfolio and entering into new partnerships with its clients. The aim is for the growth to mainly take place organically. In terms of finances, the company is on a stable foundation.

Dividend policy

Remedy’s Board of Directors has established a dividend policy aimed at maximizing ownership value through efficient allocation of capital.

The payment of any dividend is influenced by business investment needs, expected return on investments and ensuring liquidity. In the event that dividend is paid, all shares of the company are entitled to equal dividend.

Key figures

FAS (AUDITED) 2018 2017 2016
Revenue, 1 000 € 20,149 17,168 16,414
Growth in revenue, % 17.3% 4.6% 19.4%
Operating profit (EBIT), 1 000 € 0,609 2,006 3,946
Operating profit, % of revenue 3.0% 11.7% 24.0%
Result for the period under review, 1 000 € 0,532 1,469 3,166
Result for the period under review, % of revenue 2.6% 8.6% 19.3%
Balance sheet total, 1 000 € 28,261 26,652 11,190
Net cash, 1 000 € 20,089 20,694 10,348
Net gearing, % -89.9% -94.8% -137.3%
Equity ratio, % 79.1% 81.9% 74.1%
Number of personnel on average during the period under review 169 139 123*

* The method for calculating the average number of personnel has changed since the 2016 financial year, and the comparable figure is 128.